ReviewJournal of neurovirology2026
HAND in Africa: prevalence, diagnostic challenges and the search for objective markers.
Review in Journal of neurovirology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
HIV Associated Neurocognitive Disorder (HAND) affects 20-50% of people with HIV (PWH) on suppressive antiretroviral therapy, with about 72% of the 16 million global cases residing in sub-Saharan Africa. Despite this disproportionate burden, HAND remains very challenging to diagnose. The Frascati diagnostic criteria which are considered the mostly used criteria albeit with recent challenges require specialist to administer the neuropsychological batteries, making it inaccessible, literacy-dependent, and culturally biased in resource-limited African settings. This creates a significant diagnostic capacity gap. Identifying and developing biomarker-based HAND diagnostic assays are critical to the early detection and effective management of HAND among people with HIV in Africa and other resource-limited settings. This narrative review used 80 articles to critically evaluate HAND neuropathogenesis, existing diagnostic tools, and the emerging peripheral blood biomarker landscape. HIV establishes a persistent CNS reservoir that drives neuroinflammation through infected microglia, dysfunctional activation of astrocytes, and neurotoxic viral proteins mainly gp120, and Tat, independently of immune-virologic state of the PWH. Among candidate biomarkers, serum ICAM-5, serum ATP, and plasma neurofilament light chain (NfL) appear to be among the most promising candidates; validating such markers in a multicenter approach to complement Africa friendly neuro-psychological test tools will help improve on HAND diagnosis. Once some biomarkers are validated, we propose that a 3-tier multi-marker diagnostic framework that could be used in complementing validated tools, spanning primary care serum-based screening through to specialist CSF biomarker profiling could enable objective, regional friendly, and early HAND detection at the point of HIV care across Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.